Perspectives on MAO-B in aging and neurological disease: Where do we go from here?

Author： Kumar M.   Andersen Julie  

Publisher： Humana Press, Inc

ISSN： 0893-7648

Source： Molecular Neurobiology, Vol.30, Iss.1, 2004-08, pp. : 77-89

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Uterus transplantation: where do we stand today and where should we go?

By Brännström Mats   Wranning Caiza Almén  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 4, 2007-04 ,pp. : 427-429

Informa Healthcare

Access to resources Recommend Favorite

G/A polymorphism in intronic sequence affects the processing of MAO‐B gene in patients with Parkinson disease

By  

FEBS Open Bio, Vol. 586, Iss. 20, 2012-10 ,pp. : 3698-3704

John Wiley & Sons Inc

Access to resources Recommend Favorite

Palivizumab: where to from here?

By Georgescu Georgiana   Chemaly Roy F  

Expert Opinion on Biological Therapy, Vol. 9, Iss. 1, 2009-01 ,pp. : 139-147

Informa Healthcare

Access to resources Recommend Favorite

Pegasparaginase: where do we stand?

By Zeidan Amer   Wang Eunice S   Wetzler Meir  

Expert Opinion on Biological Therapy, Vol. 9, Iss. 1, 2009-01 ,pp. : 111-119

Informa Healthcare

Access to resources Recommend Favorite

Immunotherapy and immunoprevention of cancer: where do we stand?

By Cavallo Federica   Curcio Claudia   Forni Guido  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 5, 2005-05 ,pp. : 717-726

Informa Healthcare

Access to resources Recommend Favorite